Australia markets closed

Context Therapeutics Inc. (CNTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.0600-0.0200 (-0.96%)
As of 10:49AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.0800
Open2.0500
Bid2.0500 x 900
Ask2.0600 x 1300
Day's range2.0300 - 2.1000
52-week range1.2700 - 10.8700
Volume33,908
Avg. volume298,893
Market cap32.89M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results

    Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the 2022 ASCO Annual Meeting Preclinical data presented at AACR Annual Meeting showcased potential of ONA-XR and CLDN6xCD3 bispecific development program PHILADELPHIA, May 11, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treat

  • GlobeNewswire

    Context Therapeutics® Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting

    Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates monotherapy clinical activity in advanced granulosa cell tumor of the ovary Trial advanced to second stage to evaluate combination of ONA-XR with oral antiestrogen PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced

  • GlobeNewswire

    Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

    Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates strong efficacy across multiple PR+ solid tumor models First presentation of preclinical CLDN6xCD3 bispecific antibody optimization, binding properties, and T-cell dependent cytotoxicity Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m. ET PHILADELPHIA, April 11, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology co